Meanwhile, the U.K.'s Medicines and Healthcare Products Regulatory Agency updated its warnings on GLP-1 and dual GLP-1/GIP ...

Patients with a heart failure history and preserved ejection fraction appeared to benefit ...

Association driven by fewer major amputations ...

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027. The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes. These treatments can positively affect appetite, ...

Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users ...

The young girl spent nearly a week in the hospital.

Some patients have pointed to severe undisclosed side effects, including blindness, loss of brain function and organ damage.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes and cancer had reduced risk ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...